SwePub
Sök i LIBRIS databas

  Utökad sökning

(id:"swepub:oai:DiVA.org:umu-153147")
 

Sökning: (id:"swepub:oai:DiVA.org:umu-153147") > Echo- and B-Type Na...

Echo- and B-Type Natriuretic Peptide-Guided Follow-Up versus Symptom-Guided Follow-Up : Comparison of the Outcome in Ambulatory Heart Failure Patients

Bajraktari, Gani (författare)
Umeå universitet,Kardiologi,Heart Centre, Umeå
Pugliese, Nicola Riccardo (författare)
D'Agostino, Andreina (författare)
visa fler...
Rosa, Gian Marco (författare)
Ibrahimi, Pranvera (författare)
Umeå universitet,Avdelningen för medicin,Kardiologi,Heart Centre, Umeå
Perçuku, Luan (författare)
Miccoli, Mario (författare)
Galeotti, Gian Giacomo (författare)
Fabiani, Iacopo (författare)
Pedrinelli, Roberto (författare)
Henein, Michael (författare)
Umeå universitet,Kardiologi,Heart Centre, Umeå
Dini, Frank L. (författare)
visa färre...
 (creator_code:org_t)
HINDAWI LTD, 2018
2018
Engelska.
Ingår i: Cardiology Research and Practice. - : HINDAWI LTD. - 2090-8016 .- 2090-0597.
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • Recent European Society of Cardiology and American Heart Association/American College of Cardiology Guidelines did not recommend biomarker-guided therapy in the management of heart failure (HF) patients. Combination of echo- and B-type natriuretic peptide (BNP) may be an alternative approach in guiding ambulatory HF management. Our aim was to determine whether a therapy guided by echo markers of left ventricular filling pressure (LVFP), lung ultrasound (LUS) assessment of B-lines, and BNP improves outcomes of HF patients. Consecutive outpatients with LV ejection fraction (EF) <= 50% have been prospectively enrolled. In Group I (n=224), follow-up was guided by echo and BNP with the goal of achieving E-wave deceleration time (EDT) >= 150 ms, tissue Doppler index E/e' < 13, B-line numbers < 15, and BNP <= 125 pg/ml or decrease > 30%; in Group II (n=293), follow-up was clinically guided, while the remaining 277 patients (Group III) did not receive any dedicated follow-up. At 60 months, survival was 88% in Group I compared to 75% in Group II and 54% in Group III (chi(2) 53.5; p<0.0001). Survival curves exhibited statistically significant differences using Mantel-Cox analysis. The number needed to treat to spare one death was 7.9 (Group I versus Group II) and 3.8 (Group I versus Group III). At multivariate Cox regression analyses, major predictors of all-cause mortality were follow-up E/e' (HR: 1.05; p=0.0038) and BNP > 125 pg/ml or decrease <= 30% (HR: 4.90; p=0.0054), while BNP > 125 pg/ml or decrease <= 30% and B-line numbers >= 15 were associated with the combined end point of death and HF hospitalization. Evidence-based HF treatment guided by serum biomarkers and ultrasound with the goal of reducing elevated BNP and LVFP, and resolving pulmonary congestion was associated with better clinical outcomes and can be valuable in guiding ambulatory HF management.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Kardiologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Cardiac and Cardiovascular Systems (hsv//eng)

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy